News
ALXN
182.50
+1.70%
3.05
Doubling Down On Gain Therapeutics
Gain Therapeutics' has found success using its physics-based approach to finding allosteric binding sites on proteins. Gain's lead asset, GT-02287, is potentially a best-in-class Parkinson's drug. The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months.
Seeking Alpha · 12/22/2023 22:56
Biotechs post record gains in November amid improving outlook
Healthcare biotechs post record gains in november amid improving outlook. Gene therapy developers outperformed and pharma giants look for m&a opportunities in the industry. November was the best month for biotechs since november 2020. The spdr s&p biotech etf climbed 14% in november while the healthcare sector rose only 9%.
Seeking Alpha · 12/03/2023 17:00
Xencor: Data In Early 2024 Could Bring Shareholder Value
Seeking Alpha · 10/27/2023 15:56
Xencor a buy at BofA on protein therapeutics
Seeking Alpha · 05/19/2023 15:27
More
Webull provides a variety of real-time ALXN stock news. You can receive the latest news about Alexion Pharms through multiple platforms. This information may help you make smarter investment decisions.
About ALXN
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The Company’s ULTOMIRIS is a long-acting C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS is an C5 inhibitor discovered and developed by Alexion that works by inhibiting the C5 protein in the terminal complement cascade. SOLIRIS is a humanized monoclonal antibody that effectively blocks terminal complement activity at the doses prescribed.